Feedback / Questions
atebimetinib (IMM-1-104) - Immuneering
https://www.globenewswire.com/news-release/2026/01/07/3214881/0/en/Immuneering-Announces-Exceptional-64-Overall-Survival-At-12-Months-in-First-Line-Pancreatic-Cancer-Patients-Treated-with-Atebimetinib-mGnP.html
Jan 7, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next